$USPH
U S PHYSICAL THERAPY INC /NV

2023 Q2 Form 10-Q Financial Statement

#000114036123023184 Filed on May 05, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $151.5M $148.5M $131.7M
YoY Change 7.7% 12.76% 17.21%
Cost Of Revenue $119.3M $117.7M $105.1M
YoY Change 8.6% 11.93% 21.66%
Gross Profit $32.21M $30.86M $26.59M
YoY Change 4.5% 16.06% 2.67%
Gross Profit Margin 21.26% 20.78% 20.19%
Selling, General & Admin $12.15M $13.86M $11.56M
YoY Change 13.07% 19.93% 6.27%
% of Gross Profit 37.71% 44.91% 43.46%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $3.827M $3.788M $3.824M
YoY Change 10.16% -0.94% 42.69%
% of Gross Profit 11.88% 12.28% 14.38%
Operating Expenses $12.15M $13.86M $11.56M
YoY Change 13.07% 19.93% 6.27%
Operating Profit $20.06M $17.00M $15.03M
YoY Change -0.09% 13.08% 0.07%
Interest Expense -$1.625M -$2.222M -$155.0K
YoY Change -5178.13% 1333.55% -22.5%
% of Operating Profit -8.1% -13.07% -1.03%
Other Income/Expense, Net -$967.0K -$2.602M $448.0K
YoY Change 65.3% -680.8% -333.33%
Pretax Income $19.10M $14.40M $15.48M
YoY Change -2.05% -7.0% 4.38%
Income Tax $4.231M $2.969M $3.498M
% Of Pretax Income 22.16% 20.62% 22.6%
Net Earnings $10.92M $7.410M $8.799M
YoY Change -2.47% -15.79% 7.66%
Net Earnings / Revenue 7.21% 4.99% 6.68%
Basic Earnings Per Share $0.64 $0.58 $0.67
Diluted Earnings Per Share $0.64 $0.58 $0.67
COMMON SHARES
Basic Shares Outstanding 13.06M 13.03M 12.94M
Diluted Shares Outstanding 13.72M 13.03M 12.94M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $160.7M $32.60M $24.23M
YoY Change 230.93% 34.57% 35.36%
Cash & Equivalents $160.7M $32.61M $24.23M
Short-Term Investments
Other Short-Term Assets $9.924M $10.73M $4.040M
YoY Change 160.47% 165.5% 6.32%
Inventory
Prepaid Expenses
Receivables $54.29M $56.65M $67.57M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $241.8M $117.8M $95.84M
YoY Change 98.45% 22.9% 26.44%
LONG-TERM ASSETS
Property, Plant & Equipment $24.98M $24.64M $118.4M
YoY Change 3.09% -79.19% 14.61%
Goodwill $506.7M $501.3M $443.7M
YoY Change 14.44% 12.99% 23.19%
Intangibles $107.6M $109.0M $91.55M
YoY Change 16.12% 19.06% 58.95%
Long-Term Investments $12.23M $12.16M $12.42M
YoY Change -0.95% -2.11%
Other Assets $4.699M $2.593M $1.972M
YoY Change 252.51% 31.49% 31.47%
Total Long-Term Assets $757.8M $750.3M $668.0M
YoY Change 12.33% 12.32% -0.83%
TOTAL ASSETS
Total Short-Term Assets $241.8M $117.8M $95.84M
Total Long-Term Assets $757.8M $750.3M $668.0M
Total Assets $999.6M $868.1M $763.9M
YoY Change 25.51% 13.65% 1.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.674M $4.233M $6.475M
YoY Change -47.48% -34.63% -4.78%
Accrued Expenses $43.34M $45.22M $51.12M
YoY Change 5.07% -11.54% -1.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.530M $7.730M $799.0K
YoY Change 57.53% 867.46% -84.27%
Total Short-Term Liabilities $85.82M $90.83M $89.02M
YoY Change 0.84% 2.04% -1.96%
LONG-TERM LIABILITIES
Long-Term Debt $143.5M $182.7M $122.1M
YoY Change -3.65% 49.58% 637.0%
Other Long-Term Liabilities $12.78M $13.87M $76.42M
YoY Change 163.05% -81.85% 14.75%
Total Long-Term Liabilities $156.2M $196.6M $122.1M
YoY Change 1.62% 60.94% 637.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $85.82M $90.83M $89.02M
Total Long-Term Liabilities $156.2M $196.6M $122.1M
Total Liabilities $344.1M $384.4M $462.9M
YoY Change 2.37% -16.96% 43.67%
SHAREHOLDERS EQUITY
Retained Earnings $237.7M $234.8M
YoY Change 2.33%
Common Stock $172.0K $152.0K
YoY Change 13.16%
Preferred Stock
YoY Change
Treasury Stock (at cost) $31.63M $31.63M
YoY Change 0.0%
Treasury Stock Shares $2.215M
Shareholders Equity $488.5M $318.1M $301.0M
YoY Change
Total Liabilities & Shareholders Equity $999.6M $868.1M $763.9M
YoY Change 25.51% 13.65% 27.65%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $10.92M $7.410M $8.799M
YoY Change -2.47% -15.79% 7.66%
Depreciation, Depletion And Amortization $3.827M $3.788M $3.824M
YoY Change 10.16% -0.94% 42.69%
Cash From Operating Activities $27.43M $11.35M $11.65M
YoY Change 72.93% -2.58% -34.07%
INVESTING ACTIVITIES
Capital Expenditures $2.464M $2.059M -$2.528M
YoY Change -220.73% -181.45% 57.02%
Acquisitions $5.796M $11.24M
YoY Change -48.44%
Other Investing Activities -$4.515M -$10.62M -$13.42M
YoY Change -18.72% -20.83% 15.66%
Cash From Investing Activities -$6.979M -$12.68M -$15.94M
YoY Change -8.12% -20.47% 20.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $938.0K
YoY Change
Cash From Financing Activities 107.7M 2.343M -43.00K
YoY Change 569.79% -5548.84% -99.78%
NET CHANGE
Cash From Operating Activities 27.43M 11.35M 11.65M
Cash From Investing Activities -6.979M -12.68M -15.94M
Cash From Financing Activities 107.7M 2.343M -43.00K
Net Change In Cash 128.1M 1.011M -4.338M
YoY Change 426.36% -123.31% -71.04%
FREE CASH FLOW
Cash From Operating Activities $27.43M $11.35M $11.65M
Capital Expenditures $2.464M $2.059M -$2.528M
Free Cash Flow $24.97M $9.290M $14.18M
YoY Change 39.45% -34.47% -26.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
2214737
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
2214737
CY2022Q1 us-gaap Profit Loss
ProfitLoss
11982000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3788000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3824000
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1305000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1806000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
735000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1846000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1445000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1359000
CY2022Q1 usph Distributions From Unconsolidated Affiliate
DistributionsFromUnconsolidatedAffiliate
132000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12681000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15944000
CY2023Q1 us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
3297000
CY2022Q1 us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
3711000
CY2023Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
7000000
CY2022Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
35000000
CY2022Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
422000
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
332000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2343000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-43000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1011000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32605000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24229000
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
442000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
81000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1377000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
525000
CY2023Q1 usph Notes Payable Related To Purchase Of Non Controlling Interest Permanent Equity
NotesPayableRelatedToPurchaseOfNonControllingInterestPermanentEquity
0
CY2022Q1 usph Notes Payable Related To Purchase Of Non Controlling Interest Permanent Equity
NotesPayableRelatedToPurchaseOfNonControllingInterestPermanentEquity
296000
CY2023Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
532000
CY2022Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
0
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1846000
CY2022Q1 usph Gain Loss On Revaluation Of Put Right Liability
GainLossOnRevaluationOfPutRightLiability
603000
CY2022Q1 usph Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
0
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31594000
CY2022Q1 usph Notes Payable Related To Purchase Of Redeemable Non Controlling Interest Temporary Equity
NotesPayableRelatedToPurchaseOfRedeemableNonControllingInterestTemporaryEquity
246000
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000885978
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
86040000
CY2022Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
75149000
CY2023Q1 usph Rent Supplies Contract Labor And Other
RentSuppliesContractLaborAndOther
30100000
CY2022Q1 usph Rent Supplies Contract Labor And Other
RentSuppliesContractLaborAndOther
28662000
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1512000
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1305000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
117652000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
105116000
CY2023Q1 us-gaap Gross Profit
GrossProfit
30857000
CY2022Q1 us-gaap Gross Profit
GrossProfit
26588000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13859000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11556000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
16998000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
15032000
CY2023Q1 usph Relief Funds
ReliefFunds
467000
CY2022Q1 usph Relief Funds
ReliefFunds
0
CY2023Q1 usph Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
-698000
CY2022Q1 usph Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
0
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
274000
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
339000
CY2023Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
64000
CY2022Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
46000
CY2023Q1 usph Gain Loss On Revaluation Of Put Right Liability
GainLossOnRevaluationOfPutRightLiability
-149000
CY2022Q1 usph Gain Loss On Revaluation Of Put Right Liability
GainLossOnRevaluationOfPutRightLiability
603000
CY2023Q1 usph Interest Expense Debt And Other
InterestExpenseDebtAndOther
2560000
CY2022Q1 usph Interest Expense Debt And Other
InterestExpenseDebtAndOther
540000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2602000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
448000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
14396000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
15480000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2969000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3498000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
11427000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
11982000
CY2023Q1 usph Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity
NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity
2720000
CY2022Q1 usph Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity
NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity
2557000
CY2023Q1 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
1297000
CY2022Q1 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
626000
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
4017000
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
3183000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
7410000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
8799000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.58
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.58
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.67
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.67
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13025000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13025000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12937000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12937000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
3183000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6057000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
8799000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
11427000
CY2023Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.43
CY2022Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.41
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
148509000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
131704000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
11427000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
11982000
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Before Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
1817000
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Before Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
0
CY2023Q1 usph Other Comprehensive Income Loss Tax Expense Benefit At Federal And State Statutory Income Tax Rate
OtherComprehensiveIncomeLossTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-464000
CY2022Q1 usph Other Comprehensive Income Loss Tax Expense Benefit At Federal And State Statutory Income Tax Rate
OtherComprehensiveIncomeLossTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
0
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
10074000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
11982000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
4017000
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1512000
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
221000
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2132000
CY2023Q1 usph Gain Loss On Revaluation Of Put Right Liability
GainLossOnRevaluationOfPutRightLiability
-149000
CY2023Q1 usph Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
-698000
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
274000
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
339000
CY2023Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
125000
CY2022Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
93000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5999000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4676000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
796000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
2145000
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1897000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2480000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11349000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11649000
CY2023Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
2059000
CY2022Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
2528000
CY2023Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
5796000
CY2022Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
11242000
CY2023Q1 usph Payments To Acquire Redeemable Non Controlling Interest
PaymentsToAcquireRedeemableNonControllingInterest
5178000
CY2022Q1 usph Payments To Acquire Redeemable Non Controlling Interest
PaymentsToAcquireRedeemableNonControllingInterest
2211000
CY2023Q1 us-gaap Payments To Acquire Interest In Subsidiaries And Affiliates
PaymentsToAcquireInterestInSubsidiariesAndAffiliates
0
CY2022Q1 us-gaap Payments To Acquire Interest In Subsidiaries And Affiliates
PaymentsToAcquireInterestInSubsidiariesAndAffiliates
99000
CY2023Q1 us-gaap Payments For Proceeds From Limited Partnership
PaymentsForProceedsFromLimitedPartnership
-107000
CY2022Q1 us-gaap Payments For Proceeds From Limited Partnership
PaymentsForProceedsFromLimitedPartnership
-4000
CY2023Q1 usph Distributions From Unconsolidated Affiliate
DistributionsFromUnconsolidatedAffiliate
245000
CY2023Q1 us-gaap Proceeds From Repayments Of Long Term Debt And Capital Securities
ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
0
CY2022Q1 us-gaap Proceeds From Repayments Of Long Term Debt And Capital Securities
ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
-31000000
CY2023Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
938000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4338000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28567000
CY2023Q1 usph Purchase Of Business Seller Financing Portion
PurchaseOfBusinessSellerFinancingPortion
360000
CY2022Q1 usph Purchase Of Business Seller Financing Portion
PurchaseOfBusinessSellerFinancingPortion
300000
CY2023Q1 usph Notes Payable Related To Purchase Of Redeemable Non Controlling Interest Temporary Equity
NotesPayableRelatedToPurchaseOfRedeemableNonControllingInterestTemporaryEquity
611000
CY2023Q1 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
5617000
CY2022Q1 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
5327000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
317053000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2023Q1 usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
-119000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1806000
CY2023Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
5617000
CY2023Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1139000
CY2023Q1 usph Deferred Taxes Related To Redeemable Non Controlling Interest Temporary Equity
DeferredTaxesRelatedToRedeemableNonControllingInterestTemporaryEquity
137000
CY2023Q1 us-gaap Stockholders Equity Other
StockholdersEquityOther
1000
CY2023Q1 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
1297000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
7410000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1353000
CY2022Q1 usph Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans
TransferOfCompensationLiabilityForCertainStockIssuedPursuantToIncentivePlans
706000
CY2022Q1 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
380000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
319476000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
297181000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2022Q1 usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
-113000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1846000
CY2022Q1 usph Sale Of Non Controlling Interest Net Of Tax And Purchases
SaleOfNonControllingInterestNetOfTaxAndPurchases
0
CY2022Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
5327000
CY2022Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1308000
CY2022Q1 us-gaap Stockholders Equity Other
StockholdersEquityOther
186000
CY2022Q1 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
626000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
8799000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
302216000
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023Q1 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
647
CY2023Q1 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
40
CY2023Q1 usph Number Of Clinics Closed
NumberOfClinicsClosed
1
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2023Q1 usph Number Of Regions
NumberOfRegions
6
CY2022Q1 us-gaap Number Of Reporting Units
NumberOfReportingUnits
2
CY2023Q1 us-gaap Number Of Reporting Units
NumberOfReportingUnits
2
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9100000
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q1 us-gaap Interest Expense On Prepetition Liabilities Recognized In Statement Of Operations
InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations
0
CY2023Q1 us-gaap Interest Expense On Prepetition Liabilities Recognized In Statement Of Operations
InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations
0
CY2023Q1 us-gaap Interest Rate Derivative Assets At Fair Value
InterestRateDerivativeAssetsAtFairValue
3600000
CY2023Q1 us-gaap Unrealized Gain Loss On Interest Rate Cash Flow Hedges Pretax Accumulated Other Comprehensive Income Loss
UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss
-1400000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-100000
CY2023Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
3700000
CY2022Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2700000
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Use of Estimates</div> <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </span> </div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">In preparing the Company’s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, goodwill impairment, tradenames and other intangible assets, allocations of purchase price, allowance for credit losses, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates.</div>
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
108991000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
148509000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
131704000
CY2023Q1 usph Estimated Percentage Of Decrease In Payment
EstimatedPercentageOfDecreaseInPayment
0.035
CY2022Q4 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.0075
CY2021Q4 usph Percentage Of Reduction In Medicare Payments For Services Performed By A Physical Or Occupational Therapist
PercentageOfReductionInMedicarePaymentsForServicesPerformedByAPhysicalOrOccupationalTherapist
0.15
CY2023Q1 usph Period Of Federal Debt Ceiling In Connection With Deficit Reductions
PeriodOfFederalDebtCeilingInConnectionWithDeficitReductions
P10Y
CY2023Q1 usph Amount Of Reductions In Federal Spending
AmountOfReductionsInFederalSpending
1200000000000
CY2013Q4 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2021Q1 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2021Q1 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2021Q2 usph Percentage Of Payment Reduction Waived Through Enacted Legislation
PercentageOfPaymentReductionWaivedThroughEnactedLegislation
0.02
CY2023Q1 usph Extension Term For Sequester Relief Applied To All Medicare Payments
ExtensionTermForSequesterReliefAppliedToAllMedicarePayments
P3M
CY2021Q4 usph Percentage Of Sequester Relief Applied To All Medicare Payments Through Period One
PercentageOfSequesterReliefAppliedToAllMedicarePaymentsThroughPeriodOne
0.02
CY2023Q1 usph Extension Term For Sequester Relief Applied To All Medicare Payments
ExtensionTermForSequesterReliefAppliedToAllMedicarePayments
P3M
CY2021Q4 usph Percentage Of Sequester Relief Applied To All Medicare Payments Through Period Two
PercentageOfSequesterReliefAppliedToAllMedicarePaymentsThroughPeriodTwo
0.01
CY2021Q4 usph Percentage Of Sequester Relief Applied To All Medicare Payments Through Period Two
PercentageOfSequesterReliefAppliedToAllMedicarePaymentsThroughPeriodTwo
0.01
CY2022Q4 usph Percentage Of Sequester Relief Applied To All Medicare Payments Through Period Two
PercentageOfSequesterReliefAppliedToAllMedicarePaymentsThroughPeriodTwo
0.01
CY2023Q1 usph Percentage Of Increase In Payment Adjustment For Therapists Participating In Merit Based Incentive Payment System
PercentageOfIncreaseInPaymentAdjustmentForTherapistsParticipatingInMeritBasedIncentivePaymentSystem
0.01
CY2023Q1 usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
CY2023Q1 usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
CY2023Q1 usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
CY2023Q1 usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
CY2023Q1 usph Reduction In Combined Physical Therapy Speech Language Pathology Expenses
ReductionInCombinedPhysicalTherapySpeechLanguagePathologyExpenses
3000
CY2023Q1 usph Percentage Of Practice Expense Component Of Relative Value Unit
PercentageOfPracticeExpenseComponentOfRelativeValueUnit
1
CY2023Q1 usph Percentage Reduction For Service In Office Or Other Non Institutional Settings
PercentageReductionForServiceInOfficeOrOtherNonInstitutionalSettings
0.50
CY2023Q1 usph Percentage Of Payment For Outpatient Therapy Services
PercentageOfPaymentForOutpatientTherapyServices
0.85
CY2023Q1 usph Net Revenue From Medicare
NetRevenueFromMedicare
41900000
CY2022Q1 usph Net Revenue From Medicare
NetRevenueFromMedicare
35600000
CY2022Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
183694000
CY2023Q1 usph Debt Instrument Face Amount Current
DebtInstrumentFaceAmountCurrent
7730000
CY2023Q1 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
7410000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
8799000
CY2023Q1 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
119000
CY2022Q1 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-153000
CY2023Q1 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
30000
CY2022Q1 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-39000
CY2023Q1 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
7499000
CY2022Q1 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
8685000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.58
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.58
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.67
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.67
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13025000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13025000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12937000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12937000
CY2022Q4 us-gaap Goodwill
Goodwill
494101000
CY2022Q4 us-gaap Goodwill
Goodwill
494101000
CY2021Q4 us-gaap Goodwill
Goodwill
434679000
CY2023Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
5424000
CY2022 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
72674000
CY2023Q1 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
1822000
CY2022 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-4140000
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9112000
CY2023Q1 us-gaap Goodwill
Goodwill
501347000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
108755000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
37413000
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
192168000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1817000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2197000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16975000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22912000
CY2023Q1 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
7962000
CY2022Q4 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
8094000
CY2023Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
2930000
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1666000
CY2023Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
230000
CY2022Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
243000
CY2023Q1 us-gaap Dividends Payable Current
DividendsPayableCurrent
5617000
CY2022Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
0
CY2023Q1 usph Payable Related To Purchase Of Redeemable Non Controlling Interest Current
PayableRelatedToPurchaseOfRedeemableNonControllingInterestCurrent
5015000
CY2022Q4 usph Payable Related To Purchase Of Redeemable Non Controlling Interest Current
PayableRelatedToPurchaseOfRedeemableNonControllingInterestCurrent
4498000
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
1193000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1600000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3698000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45220000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1757000
CY2023Q1 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
190411000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
185555000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1861000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
1932000
CY2023Q1 us-gaap Lease Cost
LeaseCost
11771000
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
7730000
CY2022Q4 usph Debt Instrument Face Amount Current
DebtInstrumentFaceAmountCurrent
8271000
CY2022Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
408000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7863000
CY2023Q1 usph Debt Instrument Face Amount Noncurrent
DebtInstrumentFaceAmountNoncurrent
184438000
CY2023Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
1757000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
182681000
CY2022Q4 usph Debt Instrument Face Amount Noncurrent
DebtInstrumentFaceAmountNoncurrent
177284000
CY2022Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
1453000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
175831000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
11427000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
11982000
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Before Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
1817000
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Before Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
0
CY2023Q1 usph Other Comprehensive Income Loss Tax Expense Benefit At Federal And State Statutory Income Tax Rate
OtherComprehensiveIncomeLossTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-464000
CY2022Q1 usph Other Comprehensive Income Loss Tax Expense Benefit At Federal And State Statutory Income Tax Rate
OtherComprehensiveIncomeLossTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
0
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
10074000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
11982000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
4017000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
3183000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6057000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
8799000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
9365000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
8404000
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
274000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
321000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
2132000
CY2022Q1 us-gaap Lease Cost
LeaseCost
10657000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
9646000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
8617000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6281000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6011000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
27967000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
31548000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
23584000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
16065000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
16836000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
116000000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6890000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
109110000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.031
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.027
CY2023Q1 us-gaap Revenues
Revenues
148509000
CY2022Q1 us-gaap Revenues
Revenues
131704000
CY2023Q1 us-gaap Gross Profit
GrossProfit
30857000
CY2022Q1 us-gaap Gross Profit
GrossProfit
26588000
CY2023Q1 us-gaap Assets
Assets
868127000
CY2022Q1 us-gaap Assets
Assets
763863000

Files In Submission

Name View Source Status
0001140361-23-023184-index-headers.html Edgar Link pending
0001140361-23-023184-index.html Edgar Link pending
0001140361-23-023184.txt Edgar Link pending
0001140361-23-023184-xbrl.zip Edgar Link pending
brhc20052412_10q.htm Edgar Link pending
brhc20052412_ex31-1.htm Edgar Link pending
brhc20052412_ex31-2.htm Edgar Link pending
brhc20052412_ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
brhc20052412_10q_htm.xml Edgar Link completed
usph-20230331_cal.xml Edgar Link unprocessable
usph-20230331_lab.xml Edgar Link unprocessable
usph-20230331_pre.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usph-20230331.xsd Edgar Link pending
usph-20230331_def.xml Edgar Link unprocessable